Showing 1711-1720 of 2038 results for "".
- Bausch + Lomb Launches Blink Nourish and Blink Boost Lubricating Eye Drops in the UShttps://modernod.com/news/bausch-lomb-launches-blink-nourish-and-blink-boost-lubricating-eye-drops-in-the-us/2482834/Bausch + Lomb announced the US launch of Blink Nourish and Blink Boost lubricating eye drops. According to B+L, both products are preservative-free, contact-lens friendly and uniquely formulated to provide hydration and comfort for dry e
- Alcon Receives FDA Approval of Tryptyr for the Treatment of the Signs and Symptoms of Dry Eye Diseasehttps://modernod.com/news/alcon-receives-fda-approval-of-tryptyr-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2482823/Alcon announced that the FDA has approved Tryptyr (acoltremon ophthalmic solution) 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of dry eye disease (DED). Tryptyr is a first-in-class TRPM8 receptor agonist (neuromodulator) that stimulates corneal senso
- Versea Ophthalmics Announces Novel Application of Biovance Product Portfolio in Retinal Procedureshttps://modernod.com/news/versea-ophthalmics-announces-novel-application-of-biovance-product-portfolio-in-retinal-procedures/2482787/Verséa Ophthalmics has announced that results from recent application of Biovance and Biovance 3L Ocular products in macular hole repair will be presented at the upcoming Retinal World Congress (RWC) being held from May 8-11, 2025 in Fort Lauderdale, FL. The macula
- Kiora Pharmaceuticals Presents In Data Demonstrating the Potential of KIO-104 to Treat Proliferative Vitreoretinopathyhttps://modernod.com/news/kiora-pharmaceuticals-presents-in-data-demonstrating-the-potential-of-kio-104-to-treat-proliferative-vitreoretinopathy/2482784/Kiora Pharmaceuticals announced the results from a preclinical study demonstrating KIO-104 significantly reduced scar formation in an established in vivo model of proliferative vitreoretinopathy (PVR). The presentation, titled, "KIO-104, a novel small molecule inhibitor o
- Outlook Therapeutics Announces Acceptance of Resubmitted BLA by FDA for ONS-5010 as a Treatment for Wet AMDhttps://modernod.com/news/outlook-therapeutics-announces-acceptance-of-resubmitted-bla-by-fda-for-ons-5010-as-a-treatment-for-wet-amd/2482733/Outlook Therapeutics announced that the FDA has acknowledged receipt of the resubmission of the biologics license application (BLA) for ONS-5010 (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet AMD. The FDA has determined that the BLA
- Orasis Launches Presbyopia Eyedrop Qlosi in the UShttps://modernod.com/news/orasis-launches-presbyopia-eyedrop-qlosi-in-the-us/2482728/Orasis Pharmaceuticals announced that Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a novel, corrective prescription eye drop for the treatment of presbyopia in adults is now available to prescribe in the US. Qlosi’s proprietary 'EyeQ Formulation&
- Sydnexis Announces Positive CHMP Opinion in Europe for Myopia Drug Candidate SYD-101https://modernod.com/news/sydnexis-announces-positive-chmp-opinion-in-europe-for-myopia-drug-candidate-syd-101/2482722/Sydnexis announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for its proprietary low-dose atropine formulation, SYD-101, for slowing the progression of pediatric m
- Tangible Science Announces CEO Transitionhttps://modernod.com/news/tangible-science-announces-ceo-transition/2482613/Tangible Science, a provider of specialty contact lens technology, announced that Karen Havenstrite, PhD, MBA, co-founder and former Chief Technology Officer, has been appointed Chief Executive Officer. Dr. Havenstrite suceeds Victor McCray, MD, who will transition to the
- Lumibird Medical Rebrands its Japanese Subsidiaryhttps://modernod.com/news/lumibird-medical-rebrands-its-japanese-subsidiary/2482598/Lumibird Medical has announced the rebranding of its Japanese subsidiary. Formerly known as Ellex Japan, the company will now operate under the name Lumibird Medical Japan, effective immediately. Founded in Osaka in 2003, the subsidiary has grown over the past two decades,&nbs
- EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMDhttps://modernod.com/news/eyepoint-announces-first-patient-dosed-in-phase-3-lucia-trial-of-duravyu-for-wet-amd/2482563/EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD). Duravyu is an inves